Navigation Links
Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
Date:2/5/2008

s three distinct business divisions, Contract Research Services, Novel Therapies and Biomarkers.

Contract Research Services

Contract Research Services provides specialised preclinical efficacy testing primarily for drug development companies on a 'fee for service' basis. This division on a standalone basis is cash generative and profitable with a seven-year track record of providing testing services to over 72 international company clients primarily in Europe and the United States.

Novel Therapies

Novel Therapies is focused on developing its own innovative therapeutics. Through its discovery platform, Novel Therapies has identified 250 potential drug candidates, of which a subset are undergoing further evaluation and characterisation as stem cell regulators for the Group's emerging drug development pipeline.

Biomarkers

The emerging biomarker technology leverages the Company's knowledge of the behaviour of epithelial stem cells and drug-induced gene expression change to measure drug effects during treatment. Changes in gene expression can be detected within hours and at low levels of chemotherapy or radiation. The highly sensitive Biomarker technology is based on using mRNA extracted from the bulb of cells at the base of a single hair follicle as a minimally invasive process to measure gene expression changes in epithelial tissue.

Combined Business Model

Epistem is exploiting its combined business model to advance its own therapeutic candidates to late preclinical stage development. The business model integrates the discovery efforts of Novel Therapies with the efficacy testing assays of its Contract Research Services Division, to identify and characterise new drug candidates. Revenues generated by Contract Research Services and Biomarkers will assist in offsetting Novel Therapies' investment requirements for the discovery and development of its lead therapeutics. The Directors believe that licensing partnership
'/>"/>

SOURCE Epistem plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
2. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
5. Arryx Launches HOTkit(TM) Complete for Dynamic, Scientific Manipulation of Microscopic Elements
6. Cardium Completes $5.3 Million Registered Direct Offering
7. WuXi PharmaTech Completes Acquisition of AppTec
8. Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.
9. Healionics Corporation Completes Series A Financing
10. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 ... den 22. september 2015 på  http://www.openinnovationinscience.at ... Science", der finder sted i ... nylig undersøgelse af internationale forskere og videnskabsmænd ... de to største udfordringer for sundhedsvidenskaben manglen ...
(Date:7/2/2015)... 2015 College of DuPage students Sam ... invaluable real-world experiences while serving biophysics internships at the ... The students will be working as a part of ... at IIT. The internship came about from a discussion ... Dr. Kathy Finan , Biology; and Dr. Wereszczynski ...
(Date:7/2/2015)... 2, 2015 Amici Procurement Migrates ... company Amici Procurement has chosen Microsoft Cloud Solution Provider ... to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... medium-sized companies in the bio-tech sector with a unique ... purchasing cycle to help them obtain best value. Its ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... development and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... and the world's largest provider of surgical instruments to the Spine Industry. The ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3COD Students Participate in Prestigious Summer Internships 2Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... Large Well-Known Product and Continues ... of Antibody Therapeutics Pipeline -, BRITISH COLUMBIA, Canada, ... TSX Venture: IXS;, http://www.ixsbio.com ), a drug development company ... Dynamic Cross Linking,(DXL(TM)) technology, announces the development of a ...
... reported results for the quarter ended September 30, 2008.,Revenue ... to $112,000 for,the quarter ended September 30, 2007. Revenue ... compared to $715,000 for the nine months,ended September 30, ... quarter of 2008 were,$17.3 million compared to $19.8 million ...
... Residual Vascular Risk Reduction: The Global Call to Action, ... Initiative:,R3i, KEY FACTS:, Residual Risk Reduction Initiative (R3i) ... unaddressed by current standards of,care in millions of patients with ... Audubon Room, Ritz Carlton Hotel, 921 Canal Street, New Orleans, ...
Cached Biology Technology:InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 2InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement 3Dendreon Reports Third Quarter 2008 Financial Results 2Dendreon Reports Third Quarter 2008 Financial Results 3Dendreon Reports Third Quarter 2008 Financial Results 4Dendreon Reports Third Quarter 2008 Financial Results 5
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... German . Much celebration at the ... has approved funding for a long-term research project by Professors ... and Dr. Frank Spinath from Saarland University. They are studying ... 4,000 pairs of twins living in Germany. The name of ...
... to a new study from the Slone Epidemiology Center (SEC) ... age 11 had a greater likelihood of adult-onset asthma compared ... The study, which is published online in ... led by Patricia Coogan, DSc, senior epidemiologist at SEC and ...
... discovered by a Northwestern University professor and now tested ... been shown to alleviate symptoms within hours, have good ... seven days from a single dose. The ... memory -- a very different approach from existing antidepressants. ...
Cached Biology News:German Research Foundation to fund globally unique twin study on social inequality 2Abuse during childhood linked to adult-onset asthma in African-American women 2New antidepressant acts very rapidly and is long lasting 2New antidepressant acts very rapidly and is long lasting 3
See product name for description....
... Amino acid mixture excluding l-[U-14C]methionine, 1.85 ... 2% ethanol, sterilized. > 1.85 ... atom carbon. Mixture of Ala, ... Leu, Lys, Phe, Pro, Ser, Thr, ...
Request Info...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Biology Products: